In phase 1 clinical trial in T2D patients, SCO-267 increased plasma GLP-1 by 3-5 folds, GIP by 30%, and PYY by 70% after single dose and robustly suppressed glucose excursion in oGTT test (Nishizaki et al., 2021). This evidence concerns the gene GCG and type 2 diabetes mellitus.